« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | |
| Generic Name: | |
| Code Name: | IPH 2101 (anti-KIR) |
| Company: | Innate Pharma |
| FDA Clinical Phase: | 1/2 |
Description:
IPH 2101 is a human antibody that helps activate cells of the immune system to destroy cancer cells. Specifically, IPH 2101 activates anti-tumor immune …
| Brand Name: | Bexxar |
| Generic Name: | iodine I 131 tositumomab |
| Code Name: | |
| Company: | GlaxoSmithKline |
| FDA Clinical Phase: | 2 |
Description:
Bexxar is a monoclonal antibody to which radioactive iodine 131 is attached, which targets a protein called CD20| Brand Name: | Istodax |
| Generic Name: | romidepsin |
| Code Name: | depsipeptide |
| Company: | Celgene |
| FDA Clinical Phase: | 2 |
Description:
Istodax is a bicyclic depsipeptide antibiotic that binds and inhibits an …
| Brand Name: | |
| Generic Name: | sotatercept |
| Code Name: | ACE-011 |
| Company: | Celgene and Acceleron Pharma |
| FDA Clinical Phase: | 2 |
Description:
ACE-011 is a human fusion protein from the …
| Brand Name: | |
| Generic Name: | |
| Code Name: | AT9283 |
| Company: | Astex |
| FDA Clinical Phase: | 2 |
Description:
AT9283 is a kinase inhibitor that prevents cell division, thereby stopping …
| Brand Name: | |
| Generic Name: | |
| Code Name: | MAGE-A3 and NY-ESO-1 |
| Company: | University of Arkansas |
| FDA Clinical Phase: | 2/3 |
Description:
The purpose of MAGE-A3 and NY-ESO-1 immunotherapy is to generate anti-myeloma T-cells (natural immune system cells) to kill myeloma cells and nothing else.